NO2023002I1 - Lasmiditan or a pharmaceutically acceptable salt thereof - Google Patents

Lasmiditan or a pharmaceutically acceptable salt thereof

Info

Publication number
NO2023002I1
NO2023002I1 NO2023002C NO2023002C NO2023002I1 NO 2023002 I1 NO2023002 I1 NO 2023002I1 NO 2023002 C NO2023002 C NO 2023002C NO 2023002 C NO2023002 C NO 2023002C NO 2023002 I1 NO2023002 I1 NO 2023002I1
Authority
NO
Norway
Prior art keywords
lasmiditan
pharmaceutically acceptable
acceptable salt
salt
pharmaceutically
Prior art date
Application number
NO2023002C
Other languages
English (en)
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42826711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2023002(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of NO2023002I1 publication Critical patent/NO2023002I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO2023002C 2009-04-02 2023-01-05 Lasmiditan or a pharmaceutically acceptable salt thereof NO2023002I1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16609709P 2009-04-02 2009-04-02

Publications (1)

Publication Number Publication Date
NO2023002I1 true NO2023002I1 (no) 2023-01-05

Family

ID=42826711

Family Applications (2)

Application Number Title Priority Date Filing Date
NO10759491A NO2413933T3 (no) 2009-04-02 2010-04-02
NO2023002C NO2023002I1 (no) 2009-04-02 2023-01-05 Lasmiditan or a pharmaceutically acceptable salt thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO10759491A NO2413933T3 (no) 2009-04-02 2010-04-02

Country Status (25)

Country Link
US (2) US20100256187A1 (no)
EP (1) EP2413933B2 (no)
JP (8) JP5727457B2 (no)
KR (1) KR101697801B1 (no)
CN (2) CN102753171A (no)
AU (1) AU2010232497B2 (no)
CA (1) CA2757019C (no)
CY (2) CY1119785T1 (no)
DK (1) DK2413933T4 (no)
ES (1) ES2655881T5 (no)
FI (1) FIC20230001I1 (no)
FR (1) FR23C1002I2 (no)
HK (1) HK1243923A1 (no)
HR (1) HRP20171742T4 (no)
HU (2) HUE037261T2 (no)
IL (1) IL215483A (no)
LT (2) LT2413933T (no)
MX (1) MX2011010359A (no)
NL (1) NL301214I2 (no)
NO (2) NO2413933T3 (no)
NZ (1) NZ596161A (no)
PL (1) PL2413933T5 (no)
PT (1) PT2413933T (no)
SI (1) SI2413933T2 (no)
WO (1) WO2010115125A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US9943401B2 (en) 2008-04-04 2018-04-17 Eugene de Juan, Jr. Therapeutic device for pain management and vision
NZ596161A (en) * 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
EP3014345A2 (en) 2013-06-26 2016-05-04 Nexisvision, Inc. Contact lenses for refractive correction
TN2019000174A1 (en) * 2016-12-06 2020-10-05 Colucid Pharmaceuticals Inc Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
TWI826514B (zh) * 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
TR199700993T1 (xx) 1995-03-20 1998-03-21 Eli Lilly And Company 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6777428B1 (en) * 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
EP1299334B1 (en) * 2000-07-13 2008-01-16 MERCK PATENT GmbH Chiral compounds i
US6650463B2 (en) * 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US20050080112A1 (en) * 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
AU2003295782A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
AU2004232799A1 (en) * 2003-04-18 2004-11-04 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
EP1651595A2 (en) * 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
KR20060067738A (ko) * 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
NZ596161A (en) † 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists

Also Published As

Publication number Publication date
CN102753171A (zh) 2012-10-24
JP7110446B2 (ja) 2022-08-01
PL2413933T3 (pl) 2018-04-30
JP2023175694A (ja) 2023-12-12
FIC20230001I1 (fi) 2023-01-10
US20210401822A1 (en) 2021-12-30
EP2413933B2 (en) 2021-06-09
DK2413933T4 (da) 2021-08-23
CY2023001I1 (el) 2023-03-24
KR101697801B1 (ko) 2017-01-18
AU2010232497A1 (en) 2011-11-24
WO2010115125A3 (en) 2011-02-17
CA2757019C (en) 2018-05-15
ES2655881T3 (es) 2018-02-22
EP2413933A4 (en) 2012-09-19
CY1119785T1 (el) 2018-06-27
HK1243923A1 (zh) 2018-07-27
HUE037261T2 (hu) 2018-08-28
IL215483A (en) 2017-07-31
JP7566996B2 (ja) 2024-10-15
JP2016188241A (ja) 2016-11-04
IL215483A0 (en) 2011-12-29
SI2413933T2 (sl) 2021-09-30
US20100256187A1 (en) 2010-10-07
JP2022163049A (ja) 2022-10-25
JP2018087247A (ja) 2018-06-07
CA2757019A1 (en) 2010-10-07
LT2413933T (lt) 2018-02-26
JP2015013903A (ja) 2015-01-22
ES2655881T5 (es) 2021-11-25
NO2413933T3 (no) 2018-03-31
EP2413933B1 (en) 2017-11-01
CN107412230A (zh) 2017-12-01
NL301214I2 (nl) 2023-04-19
DK2413933T3 (da) 2018-01-29
EP2413933A2 (en) 2012-02-08
PL2413933T5 (pl) 2021-10-18
JP2012522805A (ja) 2012-09-27
HRP20171742T4 (hr) 2021-08-06
SI2413933T1 (en) 2018-04-30
WO2010115125A2 (en) 2010-10-07
JP7335397B2 (ja) 2023-08-29
NL301214I1 (no) 2023-01-25
HUS2300004I1 (hu) 2023-02-28
FR23C1002I1 (fr) 2023-03-10
MX2011010359A (es) 2012-02-23
HRP20171742T1 (hr) 2018-02-09
KR20110136893A (ko) 2011-12-21
JP2021152008A (ja) 2021-09-30
JP2019189617A (ja) 2019-10-31
PT2413933T (pt) 2017-12-12
LTPA2023502I1 (no) 2023-01-25
JP5727457B2 (ja) 2015-06-03
FR23C1002I2 (fr) 2023-11-24
JP6887462B2 (ja) 2021-06-16
NZ596161A (en) 2013-11-29
CY2023001I2 (el) 2023-06-09
AU2010232497B2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
NO2020006I1 (no) upadacitinib or a pharmaceutically acceptable salt thereof
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
FIC20240031I1 (fi) Sparsentaani tai sen farmaseuttisesti hyväksyttävä suola
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NO2021039I1 (no) pibrentasvir or a pharmaceutically acceptable salt thereof - forlenget SPC
NO2020037I1 (no) alpelisib eller et farmasøytisk akseptabelt salt derav
NO2021013I1 (no) filgotinib or a salt thereof
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2024006I1 (no) Piflufolastat (18F) or a pharmaceutically acceptable salt thereof
NO2023017I1 (no) Mitapivat or a pharmaceutically acceptable salt thereof, in particular mitapivat sulfate
NO2021040I1 (no) glecaprevir or a pharmaceutically acceptable salt or ester thereof- forlenget SPC
FIC20230039I1 (fi) Sedatsuridiini tai tämän farmaseuttisesti hyväksyttävä suola
NO2022031I1 (no) Voxelotor or a tautomer or pharmaceutically acceptable salt thereof
NO2017059I2 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav
NO2019012I1 (no) Enkorafenib eller et farmasøytisk akseptabelt salt eller solvat derav
NL301157I2 (nl) odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NO2021034I1 (no) pemigatinib or a pharmaceutically acceptable salt thereof
HUS000509I2 (hu) Abemaciklib vagy egy gyógyászatilag elfogadható sója
NO2021041I1 (no) remimazolam or a pharmaceutically acceptable salt thereof
NO2017024I1 (no) Elosulfase alfa eller et farmasøytisk akseptabelt salt derav
NO2019019I1 (no) Doravirin eller et farmasøytisk akseptabelt salt derav
NO2015012I2 (no) Ombitasvir, eller et farmasøytisk akseptabelt salt derav
NL300886I2 (nl) baricitinib, of een farmaceutisch aanvaardbaar zout daarvan